Donepezil Market Report 2026

The donepezil market size has grown steadily in recent years. It will grow from $1.04 billion in 2025 to $1.09 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to aging global population, rising prevalence of alzheimer’s disease, widespread adoption of cholinesterase inhibitors, improved dementia diagnosis rates, expansion of neurology treatment facilities.

The donepezil market size is expected to see steady growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to growth in elderly population worldwide, increasing awareness of early dementia treatment, rising demand for cost-effective generics, expansion of home-based cognitive care, increasing healthcare expenditure on neurodegenerative diseases. Major trends in the forecast period include rising long-term use in alzheimer’s disease management, increasing preference for oral cognitive enhancement therapies, growing demand for generic donepezil formulations, expansion of treatment in mild to moderate alzheimer’s cases, increased focus on geriatric neurology care.

The rising prevalence of Alzheimer’s disease is anticipated to drive the growth of the donepezil market in the coming years. Alzheimer’s disease is a progressive neurological disorder that leads to the degeneration and death of brain cells, resulting in memory loss, cognitive impairment, and behavioral changes. The number of Alzheimer’s cases is increasing due to factors such as an aging population, overall population growth, lifestyle-related influences, a rise in chronic conditions, genetic predispositions, and environmental exposures. Donepezil provides an effective symptomatic treatment for Alzheimer’s disease by improving cognitive function and daily living abilities through its effect on acetylcholine levels in the brain. For example, in May 2024, a report by the Alzheimer’s Association, a US-based nonprofit organization focused on Alzheimer’s care, support, and research, indicated that the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the growing incidence of Alzheimer’s is fueling the expansion of the donepezil market.

Major companies in the donepezil sector are concentrating on developing innovative delivery technologies, including once-weekly and extended-release transdermal systems, to enhance patient adherence and minimize treatment-related discomfort in individuals with Alzheimer’s. A donepezil transdermal system administers the medication through the skin at a controlled pace, bypassing first-pass metabolism and reducing the likelihood of gastrointestinal side effects commonly associated with oral administration. For example, in March 2024, Corium, Inc., a US-based biopharmaceutical firm, launched its next-generation Adlarity formulation featuring improved patch adhesion, better skin tolerability, and a more consistent 7-day release profile that ensures uninterrupted therapeutic exposure. This upgraded system was developed by Corium to simplify Alzheimer’s care by lessening the dosing burden and supporting adherence among older adults who find daily oral medications challenging.

In August 2023, Corium Innovation Inc., a US-based biopharmaceutical company, entered into a partnership with Lotus Pharmaceuticals. The collaboration aims to develop innovations such as the innovative Alzheimer’s disease treatment ADLARITY across multiple markets in Asia and establish a license agreement for ADLARITY (donepezil transdermal system), an advanced Alzheimer’s dementia therapy, in ten Asian markets. Lotus Pharmaceutical is a Taiwan-based company specializing in the commercialization of both novel and generic pharmaceuticals.

Major companies operating in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy's Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group.

North America was the largest region in the donepezil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the donepezil market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the donepezil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the donepezil market by raising the cost of imported active pharmaceutical ingredients and finished generic formulations used in Alzheimer’s disease treatment. These impacts are most visible in tablet manufacturing and retail pharmacy distribution, where pricing sensitivity is high. Regions such as North America and Asia Pacific have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced generic drug pricing, procurement planning, and inventory strategies. At the same time, tariffs have encouraged domestic generic drug manufacturing, expanded local production capacity, and strengthened regional pharmaceutical supply chains over the long term.

The donepezil market research report is one of a series of new reports that provides donepezil market statistics, including donepezil industry global market size, regional shares, competitors with a donepezil market share, detailed donepezil market segments, market trends and opportunities, and any further data you may need to thrive in the donepezil industry. This donepezil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Donepezil is a medication used to manage symptoms of Alzheimer's disease by preventing the breakdown of acetylcholine, a neurotransmitter essential for memory and cognitive function. It acts as a cholinesterase inhibitor, enhancing cognitive abilities and slowing the advancement of symptoms in individuals with mild to moderate Alzheimer's disease.

The primary dosages of donepezil are 5 mg, 10 mg, and 23 mg. Donepezil 5 mg represents a particular strength of the drug donepezil hydrochloride, which is mainly prescribed for managing dementia linked to Alzheimer's disease. It is administered through various routes, including oral and transdermal methods, and is utilized in different settings such as hospitals, clinics, and pharmacies.

The donepezil market consists of sales of orally disintegrating tablets, experimental and niche products, active pharmaceutical ingredients, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.